Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp is demonstrating strong financial performance, with an anticipated operating margin of approximately 24% for FY25, reflecting a year-over-year improvement of 390 basis points, which is above consensus expectations. The company's gross margin also improved by 240 basis points year-over-year, highlighting effective cost management and pricing strategies. Significant growth in the plasma segment, driven by premium pricing from technology upgrades and new account openings in the transfusion management area, further supports a positive outlook for future revenue and operational performance.

Haemonetics Corp has experienced a decline in revenue across several segments, with Blood Center sales showing a 2.8% organic decline to $68.5 million, and Plasma sales dropping 9.1% organic to $138.6 million, both falling short of market expectations. Furthermore, the company's guidance indicates a pessimistic outlook, with a revised expectation for organic Hospital growth between 12-14%, down from the previous 14-17%, and Blood Center growth projected to worsen to a decline of 5-7% compared to earlier estimates. Overall organic revenue growth slowed drastically to -0.3% in F3Q25 from 3.7% in F2Q25, coupled with reduced top-line expectations and narrowing of the non-GAAP EPS range, suggesting challenges in maintaining profitability.